首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy
【24h】

Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy

机译:妇科癌症患者组合止吐抑制治疗接受TC化疗的评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aim: The incidence of delayed chemotherapy-induced nausea and vomiting (CINV), especially nausea, in gynecologic cancer patients who receive paclitaxel and carboplatin (TC) chemotherapy is unclear. We assessed risk factors for delayed CINV in these patients, and examined whether it was controlled with combination antiemetic therapy. Materials and Methods: Data were pooled from two prospective studies, and compared between the two antiemetic prophylaxis groups using inverse probability of treatment weighted (IPTW) analysis. Results: Among the 182 evaluable patients (mean age: 56.2 years), three antiemetics gave better overall control than two for delayed nausea (42.9% vs. 57.4%,) and vomiting (13.8% vs. 34.5%). Risk factor for delayed nausea was age [odds ratio (OR)=0.953; p=0.0898[and use of two antiemetics (vs. three antiemetics) for delayed vomiting (OR=0.304; p=0.0732). Conclusion: A combination of three antiemetics controls delayed CINV among patients who undergo TC chemotherapy. Identification of risk factors can facilitate personalized treatments.
机译:背景/目的:延迟化疗诱导的恶心和呕吐(CINV),尤其是恶心,在接受紫杉醇和卡铂(TC)化学疗法的妇科癌症患者中的发病率尚不清楚。我们评估了这些患者延迟Cinv的风险因素,并检查了是否被组合止吐疗法控制。材料和方法:从两项前瞻性研究中汇集了数据,并使用逆概率对加权(IPTW)分析的反概率进行比较。结果:182名可评估患者(平均年龄:56.2岁)中,三种止血剂对延迟恶心(42.9%vs.57.4%,)和呕吐(5.8%vs.3.5%)提供了更好的整体控制。延迟恶心的危险因素是年龄[赔率比(或)= 0.953; P = 0.0898 [和使用两个止吐学(与三个助剂)延迟呕吐(或= 0.304; p = 0.0732)。结论:三种止吐剂控制患者延迟CINV,患有TC化疗的患者。识别风险因素可以促进个性化治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号